1
|
Ponz de Leon M and Di Gregorio C:
Pathology of colorectal cancer. Dig Liver Dis. 33:372–388. 2001.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Le Bras GF, Taubenslag KJ and Andl CD: The
regulation of cell-cell adhesion during epithelial-mesenchymal
transition, motility and tumor progression. Cell Adh Migr.
6:365–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Tsanou E, Peschos D, Batistatou A,
Charalabopoulos A and Charalabopoulos K: The E-cadherin adhesion
molecule and colorectal cancer. A global literature approach.
Anticancer Res. 28:3815–3826. 2008.PubMed/NCBI
|
4
|
Wang X, Tully O, Ngo B, Zitin M and Mullin
JM: Epithelial tight junctional changes in colorectal cancer
tissues. ScientificWorldJournal. 11:826–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kanczuga-Koda L: Gap junctions and their
role in physiology and pathology of the digestive tract. Postepy
Hig Med Dosw (Online). 58:1581652004.(In Polish). PubMed/NCBI
|
6
|
Turksen K and Troy TC: Junctions gone bad:
claudins and loss of the barrier in cancer. Biochim Biophys Acta.
1816:73–79. 2011.PubMed/NCBI
|
7
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Sipos F and Galamb O:
Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions
in the colon. World J Gastroenterol. 18:601–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Skrzypczak M, Goryca K, Rubel T, et al:
Modeling oncogenic signaling in colon tumors by multidirectional
analyses of microarray data directed for maximization of analytical
reliability. PLoS One. 5:e130912010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Khan K, Hardy R, Haq A, Ogunbiyi O, Morton
D and Chidgey M: Desmocollin switching in colorectal cancer. Br J
Cancer. 95:1367–1370. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Shimoyama Y, Yoshida T, Terada M, et al:
Molecular cloning of a human Ca2+-dependent cell-cell adhesion
molecule homologous to mouse placental cadherin: its low expression
in human placental tissues. J Cell Biol. 109:1787–1794. 1989.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Hardy RG, Tselepis C, Hoyland J, et al:
Aberrant P-cadherin expression is an early event in hyperplastic
and dysplastic transformation in the colon. Gut. 50:513–519. 2002.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Kamposioras K, Konstantara A, Kotoula V,
et al: The prognostic significance of WNT pathway in
surgically-treated colorectal cancer: β-catenin expression predicts
for disease-free survival. Anticancer Res. 33:4573–4584.
2013.PubMed/NCBI
|
14
|
Milicic A, Harrison LA, Goodlad R, et al:
Ectopic expression of P-cadherin correlates with promoter
hypomethylation early in colorectal carcinogenesis and enhanced
intestinal crypt fission in vivo. Cancer Res. 68:7760–7768. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Hibi K, Goto T, Mizukami H, et al:
Demethylation of the CDH3 gene is frequently detected in advanced
colorectal cancer. Anticancer Res. 29:2215–2217. 2009.PubMed/NCBI
|
16
|
Yoshioka H, Yamamoto S, Hanaoka H, et al:
In vivo therapeutic effect of CDH3/P-cadherin-targeting
radioimmunotherapy. Cancer Immunol Immunother. 61:1211–1220. 2012.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Kaur H, Phillips-Mason PJ, Burden-Gulley
SM, et al: Cadherin-11, a marker of the mesenchymal phenotype,
regulates glioblastoma cell migration and survival in vivo. Mol
Cancer Res. 10:293–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chu K, Cheng CJ, Ye X, et al: Cadherin-11
promotes the metastasis of prostate cancer cells to bone. Mol
Cancer Res. 6:1259–1267. 2008. View Article : Google Scholar : PubMed/NCBI
|
19
|
Tamura D, Hiraga T, Myoui A, Yoshikawa H
and Yoneda T: Cadherin-11-mediated interactions with bone marrow
stromal/osteoblastic cells support selective colonization of breast
cancer cells in bone. Int J Oncol. 33:17–24. 2008.PubMed/NCBI
|
20
|
Torres S, Bartolome RA, Mendes M, et al:
Proteome profiling of cancer-associated fibroblasts identifies
novel proinflammatory signatures and prognostic markers for
colorectal cancer. Clin Cancer Res. 19:6006–6019. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Li L, Ying J, Li H, et al: The human
cadherin 11 is a pro-apoptotic tumor suppressor modulating cell
stemness through Wnt/β-catenin signaling and silenced in common
carcinomas. Oncogene. 31:3901–3912. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Carmona FJ, Villanueva A, Vidal A, et al:
Epigenetic disruption of cadherin-11 in human cancer metastasis. J
Pathol. 228:230–240. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Hruz T, Laule O, Szabo G, et al:
Genevestigator v3: a reference expression database for the
meta-analysis of transcriptomes. Adv Bioinformatics.
2008:4207472008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Blons H, Laccourreye O, Houllier AM, et
al: Delineation and candidate gene mutation screening of the 18q22
minimal region of deletion in head and neck squamous cell
carcinoma. Oncogene. 21:5016–5023. 2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
Chernoff J: Protein tyrosine phosphatases
as negative regulators of mitogenic signaling. J Cell Physiol.
180:173–81. 1999. View Article : Google Scholar : PubMed/NCBI
|
26
|
Serra-Pages C, Kedersha NL, Fazikas L, et
al: The LAR transmembrane protein tyrosine phosphatase and a
coiled-coil LAR-interacting protein co-localize at focal adhesions.
EMBO J. 14:2827–2838. 1995.PubMed/NCBI
|
27
|
Symons JR, LeVea CM and Mooney RA:
Expression of the leucocyte common antigen-related (LAR) tyrosine
phosphatase is regulated by cell density through functional
E-cadherin complexes. Biochem J. 365:513–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
28
|
Bonvini P, An WG, Rosolen A, et al:
Geldanamycin abrogates ErbB2 association with proteasome-resistant
beta-catenin in melanoma cells, increases beta-catenin-E-cadherin
association, and decreases beta-catenin-sensitive transcription.
Cancer Res. 61:1671–1677. 2001.PubMed/NCBI
|
29
|
Wang Z, Shen D, Parsons DW, et al:
Mutational analysis of the tyrosine phosphatome in colorectal
cancers. Science. 304:1164–1166. 2004. View Article : Google Scholar : PubMed/NCBI
|
30
|
Knosel T, Chen Y, Hotovy S, Settmacher U,
Altendorf-Hofmann A and Petersen I: Loss of desmocollin 1–3 and
homeobox genes PITX1 and CDX2 are associated with tumor progression
and survival in colorectal carcinoma. Int J Colorectal Dis.
27:1391–1399. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Singh AB, Sharma A, Smith JJ, et al:
Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin
expression in colon cancer cells. Gastroenterology. 141:2140–2153.
2011. View Article : Google Scholar : PubMed/NCBI
|
32
|
Huo Q, Kinugasa T, Wang L, et al:
Claudin-1 protein is a major factor involved in the tumorigenesis
of colorectal cancer. Anticancer Res. 29:851–857. 2009.PubMed/NCBI
|
33
|
Kinugasa T, Huo Q, Higashi D, et al:
Selective up-regulation of claudin-1 and claudin-2 in colorectal
cancer. Anticancer Res. 27:3729–3734. 2007.PubMed/NCBI
|
34
|
Grone J, Weber B, Staub E, et al:
Differential expression of genes encoding tight junction proteins
in colorectal cancer: frequent dysregulation of claudin-1, −8 and
−12. Int J Colorectal Dis. 22:651–659. 2007. View Article : Google Scholar : PubMed/NCBI
|
35
|
Pitule P, Vycital O, Bruha J, et al:
Differential expression and prognostic role of selected genes in
colorectal cancer patients. Anticancer Res. 33:4855–4865.
2013.PubMed/NCBI
|
36
|
Rahner C, Mitic LL and Anderson JM:
Heterogeneity in expression and subcellular localization of
claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut.
Gastroenterology. 120:411–422. 2001. View Article : Google Scholar : PubMed/NCBI
|
37
|
Soini Y: Expression of claudins 1, 2, 3,
4, 5 and 7 in various types of tumours. Histopathology. 46:551–560.
2005. View Article : Google Scholar : PubMed/NCBI
|
38
|
Escudero-Esparza A, Jiang WG and Martin
TA: Claudin-5 participates in the regulation of endothelial cell
motility. Mol Cell Biochem. 362:71–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
39
|
Herr D, Sallmann A, Bekes I, et al: VEGF
induces ascites in ovarian cancer patients via increasing
peritoneal permeability by downregulation of Claudin 5. Gynecol
Oncol. 127:210–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
40
|
Zeissig S, Burgel N, Gunzel D, et al:
Changes in expression and distribution of claudin 2, 5 and 8 lead
to discontinuous tight junctions and barrier dysfunction in active
Crohn's disease. Gut. 56:61–72. 2007. View Article : Google Scholar : PubMed/NCBI
|
41
|
Fujita H, Chiba H, Yokozaki H, et al:
Differential expression and subcellular localization of claudin-7,
−8, −12, −13, and −15 along the mouse intestine. J Histochem
Cytochem. 54:933–944. 2006. View Article : Google Scholar : PubMed/NCBI
|
42
|
Arimura Y, Nagaishi K and Hosokawa M:
Dynamics of claudins expression in colitis and colitis-associated
cancer in rat. Methods Mol Biol. 762:409–425. 2011. View Article : Google Scholar : PubMed/NCBI
|
43
|
Oster B, Thorsen K, Lamy P, et al:
Identification and validation of highly frequent CpG island
hypermethylation in colorectal adenomas and carcinomas. Int J
Cancer. 129:2855–2866. 2011. View Article : Google Scholar : PubMed/NCBI
|
44
|
Citi S, Amorosi A, Franconi F, Giotti A
and Zampi G: Cingulin, a specific protein component of tight
junctions is expressed in normal and neoplastic human epithelial
tissues. Am J Pathol. 138:781–789. 1991.PubMed/NCBI
|
45
|
Guillemot L and Citi S: Cingulin regulates
claudin-2 expression and cell proliferation through the small
GTPase RhoA. Mol Biol Cell. 17:3569–3577. 2006. View Article : Google Scholar : PubMed/NCBI
|
46
|
Papageorgis P, Lambert AW, Ozturk S, et
al: Smad signaling is required to maintain epigenetic silencing
during breast cancer progression. Cancer Res. 70:968–978. 2010.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Losi L, Parenti S, Ferrarini F, et al:
Down-regulation of μ-protocadherin expression is a common event in
colorectal carcinogenesis. Hum Pathol. 42:960–971. 2011. View Article : Google Scholar : PubMed/NCBI
|
48
|
Beukers W, Hercegovac A, Vermeij M, et al:
Hypermethylation of the polycomb group target gene PCDH7 in bladder
tumors from patients of all ages. J Urol. 190:311–316. 2013.
View Article : Google Scholar : PubMed/NCBI
|
49
|
Li VS, Yuen ST, Chan TL, et al: Frequent
inactivation of axon guidance molecule RGMA in human colon cancer
through genetic and epigenetic mechanisms. Gastroenterology.
137:176–187. 2009. View Article : Google Scholar : PubMed/NCBI
|
50
|
Yamauchi M, Morikawa T, Kuchiba A, et al:
Assessment of colorectal cancer molecular features along bowel
subsites challenges the conception of distinct dichotomy of
proximal versus distal colorectum. Gut. 61:847–854. 2012.
View Article : Google Scholar : PubMed/NCBI
|
51
|
Koestler DC, Li J, Baron JA, et al:
Distinct patterns of DNA methylation in conventional adenomas
involving the right and left colon. Mod Pathol. 27:145–155. 2014.
View Article : Google Scholar : PubMed/NCBI
|